Prevention of Plasmodium vivax malaria recurrence: Efficacy of the standard total dose of primaquine administered over 3 days

Acta Tropica

Volumn 112, Issue 2, 2009, Pages 188-192

  Carmona Fonseca, Jaime ^a   Maestre, Amanda ^a  

^a UNIVERSIDAD DE ANTIOQUIA   (Colombia)

Author keywords

Antimalarials; Plasmodium vivax; Primaquine; Relapse

Indexed keywords

CHLOROQUINE; PRIMAQUINE;

ANTIBIOTICS; DISEASE CONTROL; DISEASE TREATMENT; DRUG PRESCRIBING; MALARIA;

ADULT; ARTICLE; CLINICAL TRIAL; COLOMBIA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; ENDEMIC DISEASE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; PLASMODIUM VIVAX MALARIA; RECURRENT INFECTION; RELAPSE;

ADOLESCENT; ADULT; ANTIMALARIALS; CHEMOPREVENTION; CHILD; CHILD, PRESCHOOL; COLOMBIA; FEMALE; HUMANS; INFANT; MALARIA, VIVAX; MALE; MIDDLE AGED; PRIMAQUINE; RECURRENCE; TREATMENT OUTCOME; YOUNG ADULT;

COLOMBIA; SOUTH AMERICA;

PLASMODIUM VIVAX;

EID: 70249139111     PISSN: 0001706X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.actatropica.2009.07.024     Document Type: Article

References (41)

1. Abdon N., Pinto A., Silva R., and de Souza J. Avaliação da resposta aos esquemas de tratamento reduzidos para malária vivax. Rev. Soc. Bras. Med. Trop. 34 (2001) 343-1343
2. Álvarez G., Piñeros J., Tobón A., Ríos A., Maestre A., Blair S., and Carmona-Fonseca J. Efficacy of three chloroquine-primaquine regimens for treatment of Plasmodium vivax malaria in Colombia. Am. J. Trop. Med. Hyg. 75 (2006) 605-609
3. Alving A., Arnold J., Hockwald R., Clayman C., Dern R., and Beutler E. Potentiation of the curative action of primaquine in vivax malaria by quinine and chloroquine. J. Lab. Clin. Med. 46 (1955) 301-306
4. Baird J. Chloroquine resistance in Plasmodium vivax. Antimicrob. Agents Chemother. 48 (2004) 4075-4083
5. Baird J. Effectiveness of antimalarial drugs. New Engl. J. Med. 352 (2005) 1565-1577
6. Baird J., Leksana B., Masbar S., Fryauff D., Sutanihardja M., Suradi L., Suradi, Wignall F.S., and Hoffman S.L. Diagnosis of resistance to chloroquine by Plasmodium vivax: timing of recurrence and whole blood chloroquine levels. Am. J. Trop. Med. Hyg. 56 (1997) 621-626
7. Blair S., Tobón A., Echeverri M., Álvarez G., and Carmona-Fonseca J. Adecuada respuesta clínica y parasitológica de Plasmodium vivax a la cloroquina en Colombia (Turbo, Antioquia), 2001. Infection 6 (2002) 21-26
8. Bray P., Deed S., Fox E., Kalkanidis M., Mungthin M., Deady L., and Tilley L. Primaquine synergises the activity of chloroquine against chloroquine-resistant P. falciparum. Biochem. Pharmacol. 70 (2005) 1158-1166
9. Carmona-Fonseca, J. 2003. La malaria en Colombia, Antioquia y las zonas de Urabá y Bajo Cauca: panorama para interpretar la falla terapéutica antimalárica. Parte 1. Iatreia 16, 299-318.
10. Carmona-Fonseca, J. 2004. La malaria en Colombia, Antioquia y las zonas de Urabá y Bajo Cauca: panorama para interpretar la falla terapéutica antimalárica. Parte 2. Iatreia 17, 34-53.
11. Carmona-Fonseca J. Profilaxis primaria con primaquina para el paludismo: revision. Anuario Enfermedades Infecciosas (Medellín) 2 (2005) 251-284
12. Carmona-Fonseca J., Álvarez G., and Blair S. Malaria por Plasmodium vivax: curación del ataque agudo con tres dosis diferentes de primaquina y dosis fija de cloroquina. Antioquia, Colombia, 2003-2004. Biomédica 26 (2006) 353-365
13. Carmona-Fonseca J., Álvarez G., Ríos A., and Vásquez M. Deficiencia de glucosa 6-fostato deshidrogenasa en hombres sanos y en pacientes maláricos; Turbo (Antioquia, Colombia). Rev. Bras. Epidemiol. 11 (2008) 252-265
14. Carmona-Fonseca J., Alvarez G., and Maestre A. Methemoglobinemia and adverse events in Plasmodium vivax malaria patients associated with high doses of primaquine treatment. Am. J. Trop. Med. Hyg. 200 80 (2009) 188-193
15. Castillo C., Osorio L., and Palma G. Assessment of therapeutic response of Plasmodium vivax and Plasmodium falciparum to chloroquine in a malaria transmission free area in Colombia. Mem. Inst. Oswaldo Cruz 97 (2002) 559-562
16. Colombia, 1999. Colombia, Ministerio de Salud. Guía de atención clínica para el diagnóstico y tratamiento de la malaria. Minsalud, Bogotá.
17. Colombia, 2006. Colombia, Ministerio de la Protección Social. Plan de implementación de combinaciones terapéuticas con derivados de artemisinina en áreas de alta transmisión de malaria en Colombia. Minprotección, Bogotá.
18. Collins W., and Jeffery G. Primaquine resistance in Plasmodium vivax. Am. J. Trop. Med. Hyg. 55 (1996) 243-249
19. Duarte E., Pang L., Ribeiro L., and Fontes C. Association of subtherapeutic dosages of a standard drug regimen with failures in preventing relapses of vivax malaria. Am. J. Trop. Med. Hyg. 65 (2001) 471-476
20. Edgcomb J. Primaquine, SN 13272, a new curative agent in vivax malaria: a preliminary report. J. Natl. Malaria Soc. 9 (1950) 285-292
21. Fryauff D., Cryz S., Widjaja H., Mouzin E., Church L., Sutamihardja M.A., Richards A.L., Subianto B., and Hoffman S.L. Humoral immune response to tetanus-diphtheria vaccine given during extended use of chloroquine or primaquine malaria chemoprophylaxis. J. Infect. Dis. 177 (1998) 1762-1765
22. Fryauff D., Church L., Richards A., Widjaja H., Mouzin E., Ratiwayanto S., Hadiputranto H., Sutamihardja M.A., Richie T.L., Subianto B., Tjitra E., and Hoffman S.L. Lymphocyte response to tetanus toxoid among Indonesian men immunized with tetanus-diphtheria during extended chloroquine or primaquine prophylaxis. J. Infect. Dis. 176 (1997) 1644-1648
23. Fryauff D., Mouzin E., Church L., Ratiwayanto S., Hadiputranto H., Sutamihardja M.A., Widjaja H., Corradin G., Subianto B., and Hoffman S.L. Lymphocyte response to tetanus toxin T-cell epitopes: effects of tetanus vaccination and concurrent malaria prophylaxis. Vaccine 17 (1999) 59-63
24. Galappaththy G., Omari A., and Tharyan P. Primaquine for preventing relapses in people with Plasmodium vivax malaria. Cochrane Database Syst. Rev. Issue 1 (2007) Review
25. Goller J., Jolley D., Ringwald P., and Biggs B. Regional differences in the response of Plasmodium vivax malaria to primaquine as anti-relapse therapy. Am. J. Trop. Med. Hyg. 76 (2007) 203-207
26. Hulley S., Cummings S., Browner W., Grady D., Hearst N., and Newman T. Designing Clinical Research. 2nd ed. (2001), Lippincott Williams & Wilkins, Philadelphia pp. 143-174
27. Kshirsagar N. Malaria: anti malarial resistance and policy ramifications and challenges. J. Postgrad. Med. 52 (2006) 291-293
28. Lacharme L., Carmona-Fonseca J., Tobón A., and Blair S. Respuesta de P. vivax al esquema terapéutico cloroquina-primaquina en Zaragoza y Turbo, Colombia, 1998. Infection 2 (1998) 90-94
29. Litter M. Compendio de farmacología. 4th ed. (1988), El Ateneo, Buenos Aires pp. 794-805
30. López-Antuñano F. In: Lopez-Antuñano S.G. (Ed). Diagnostico de malaria vol. 512 (1988), OPS-OMS, WA pp. 39-50
31. Lozano J., and Dennis R. In: Ruiz A., and Morillo L. (Eds). Epidemiología clínica. Investigación clínica aplicada (2004), Editorial Panamericana, Bogotá 233-264
32. Lwanga S., and Lameshow S. Determinación del Tamaño Muestral en los Estudios Sanitarios. Manual Prático (1991), OMS, Geneva
33. Peters W. The chemotherapy-immunity interface. In: Peters W. (Ed). Chemotherapy and Drug Resistance in Malaria vol. 2 (1987), Academic Press, London 893-919
34. Phillips E., Keystone J., and Kain K. Failure of combined chloroquine and high dose primaquine therapy for Plasmodium vivax malaria acquired in Guyana, South America. Clin. Infect. Dis. 23 (1996) 1171-1173
35. Ruebush T., Zegarra J., Cairo J., Andersen E., Green M., Pillai D.R., Marquiño W., Huilca M., Arévalo E., Garcia C., Solary L., and Kain K.C. Chloroquine-resistant Plasmodium vivax malaria in Peru. Am. J. Trop. Med. Hyg. 69 (2003) 548-552
36. Schwartz E., Regev-Yochay G., and Kurnik D. Short report: a consideration of primaquine dose adjustment for radical cure of Plasmodium vivax malaria. Am. J. Trop. Med. Hyg. 63 (2000) 393-395
37. Target G. Interactions between chemotherapy and immunity. In: Peters W., and Richards W. (Eds). Antimalarial drugs I. Handbook of experimental pharmacology (1984), Springer-Verlag, New York 321-348
38. Whitby M. Drug resistant Plasmodium vivax malaria. J. Antimicrob. Chemother. 40 (1997) 749-752
39. WHO. Technical Report Series No. 805. World Health Organization. Practical Chemotherapy of Malaria (1990), WHO, Geneva
40. World Health Organization (WHO). Guidelines for the treatment of malaria. Documento WHO/HTM/MAL/2006. 1108 (2006), WHO, Geneva
41. Xunta de Galicia (España), Organización Panamericana de la Salud, 2006. Epidat 3.1. Programa para el análisis epidemiológico de datos tabulados.